Eterna Therapeutics Inc. (ERNA)
- Previous Close
2.3800 - Open
2.3500 - Bid --
- Ask --
- Day's Range
2.0300 - 2.3600 - 52 Week Range
0.8400 - 2.9900 - Volume
23,509 - Avg. Volume
9,268 - Market Cap (intraday)
11.47M - Beta (5Y Monthly) 8.21
- PE Ratio (TTM)
-- - EPS (TTM)
-4.0800 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
eternatx.comRecent News: ERNA
Performance Overview: ERNA
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ERNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ERNA
Valuation Measures
Market Cap
12.71M
Enterprise Value
46.98M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
186.97
Price/Book (mrq)
5.70
Enterprise Value/Revenue
690.93
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.19%
Return on Equity (ttm)
-302.20%
Revenue (ttm)
68k
Net Income Avi to Common (ttm)
-21.68M
Diluted EPS (ttm)
-4.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
7.58M
Total Debt/Equity (mrq)
1,873.85%
Levered Free Cash Flow (ttm)
-13.45M
Research Analysis: ERNA
Company Insights: ERNA
ERNA does not have Company Insights